跳转至内容
Merck

R1781

Sigma-Aldrich

雷莫拉宁

别名:

A 16686, Antibiotic A 16686

登录查看公司和协议定价


About This Item

CAS号:
MDL號碼:
分類程式碼代碼:
51102829
NACRES:
NA.85

化驗

≥75% (as ramoplanin A2)

形狀

powder

溶解度

H2O: soluble 10 mg/mL

抗生素活性譜

Gram-positive bacteria

作用方式

cell wall synthesis | interferes

運輸包裝

dry ice

儲存溫度

−20°C

InChI

1S/C106H170ClN21O30/c1-8-9-10-11-15-22-80(140)114-75(50-78(110)138)96(147)118-76(51-79(111)139)97(148)124-86(60-25-36-66(133)37-26-60)102(153)117-72(21-17-46-109)92(143)120-83(56(6)130)100(151)126-89(63-31-42-69(136)43-32-63)105(156)127-88(62-29-40-68(135)41-30-62)104(155)121-82(55(5)129)99(150)119-74(48-58-18-13-12-14-19-58)95(146)116-71(20-16-45-108)93(144)123-87(61-27-38-67(134)39-28-61)103(154)122-84(57(7)131)101(152)125-85(59-23-34-65(132)35-24-59)98(149)112-52-81(141)115-73(47-53(2)3)94(145)113-54(4)91(142)128-90(106(157)158)64-33-44-77(137)70(107)49-64/h10-15,18-19,22,53-57,59-77,82-90,129-137H,8-9,16-17,20-21,23-52,108-109H2,1-7H3,(H2,110,138)(H2,111,139)(H,112,149)(H,113,145)(H,114,140)(H,115,141)(H,116,146)(H,117,153)(H,118,147)(H,119,150)(H,120,143)(H,121,155)(H,122,154)(H,123,144)(H,124,148)(H,125,152)(H,126,151)(H,127,156)(H,128,142)(H,157,158)/b11-10-,22-15-/t54-,55+,56+,57+,59?,60?,61?,62?,63?,64?,65?,66?,67?,68?,69?,70?,71-,72-,73+,74+,75+,76?,77?,82+,83-,84+,85?,86-,87?,88-,89-,90?/m1/s1

InChI 密鑰

FSBZBQUUCNYWOK-YIOPJBSBSA-N

相关类别

一般說明

Chemical structure: glycopeptide
Ramoplanin is a glycolipodepsipeptide antibiotic produced by Actinoplanes sp. It is a complex of structurally related molcules, with ramoplanin A2 as the primary component. It is used for in vitro susceptibility testing and to study antibiotic-resistant enterococci.

生化/生理作用

Ramoplatin is an antimicrobial which is effective against Gram-positive bacteria, including vancomycin-resistant enterococci. It acts by inhibiting bacterial cell wall synthesis, although its mechanism of action is different from that of glycopeptide-based synthesis inhibitors.

其他說明

Keep container tightly closed in a dry and well-ventilated place.

象形圖

Corrosion

訊號詞

Danger

危險聲明

危險分類

Eye Dam. 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

nwg

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ashwin Balagopal et al.
Current opinion in pharmacology, 7(5), 455-458 (2007-07-24)
Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as
Romeo Ciabatti et al.
Journal of medicinal chemistry, 50(13), 3077-3085 (2007-06-05)
Ramoplanin is a glycolipodepsipeptide antibiotic active against Gram-positive bacteria including vancomycin-resistant enterococci. Ramoplanin inhibits bacterial cell wall biosynthesis by a mechanism different from that of glycopeptides and hence does not show cross-resistance with these antibiotics. The systemic use of ramoplanin
Herman Goossens et al.
The Journal of antimicrobial chemotherapy, 51 Suppl 3, iii5-ii12 (2003-06-13)
A survey in eight European countries, including 13 hospitals, of vancomycin-resistant enterococci (VRE) in at-risk hospital wards (such as the ICU and the haematology ward) was performed in 2001, and the in vitro susceptibility of the isolates ramoplanin and other
Matthew F Ewles et al.
Biomedical chromatography : BMC, 25(9), 995-1002 (2010-12-15)
A method has been developed and validated for the quantification of ramoplanin, a 2554 Da peptide antibiotic, in human dried blood spots using high-performance liquid chromatography with tandem mass spectrometric detection. The validation data meet FDA acceptance criteria for bioanalytical assays
Françoise Van Bambeke
Current opinion in investigational drugs (London, England : 2000), 7(8), 740-749 (2006-09-08)
Hemi-synthetic derivatives of glycopeptides have demonstrated bactericidal activity towards Gram-positive bacteria, including vancomycin-resistant strains (oritavancin and telavancin), and a prolonged half-life, allowing for once-daily (oritavancin and telavancin) or once-weekly (dalbavancin) administration. These compounds have proved effective for the treatment of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门